COMPANY

Riboscience

HQ: Palo Alto, CA source · riboscience.com ↗ · West Coast

Keywords: oncology Metastatic Colorectal Cancer Advanced Colorectal Cancer Advanced Unresectable Hepatocellular Carcinoma Expanded Access in Pancreatic Cancer RBS2418

Location: Palo Alto, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)6NIH grants

Timeline

Apr 10, 2026 Trial start Phase 2: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma source ↗
Sep 12, 2025 Grant Government grant — STTR: $306,739 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Jan 17, 2025 Trial start Phase 2: Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer source ↗
Jul 11, 2022 Trial start Phase 1: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors source ↗

Upcoming milestones

2027-04 (ESTIMATED) · Phase 2 · Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma · NCT07175441
2027-04 (ESTIMATED) · Phase 1 · Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors · NCT05270213
2027-12 (ESTIMATED) · Phase 2 · Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer · NCT06824064

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 12, 2025 Government grant — STTR: $306,739 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06824064	Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer	Phase 2	Recruiting	Jan 17, 2025	2027-12 (estimated)
NCT07175441	Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Apr 10, 2026	2027-04 (estimated)
NCT05270213	Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors	Phase 1	Recruiting	Jul 11, 2022	2027-04 (estimated)
NCT05683470	Expanded Access RBS2418 Treatment	Not listed	No longer available	Not listed	Not listed

NIH awards 6

Annual award amounts. Total $6.0M.

Aug 19, 2021 NIH award 5R44DA050368-03 FY2021: $995,102 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent double anti-HCV nucleosi source ↗
Aug 6, 2020 NIH award 5R44DA050368-02 FY2020: $995,102 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent double anti-HCV nucleosi source ↗
Sep 9, 2019 NIH award 1R44DA050368-01 FY2019: $995,102 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent double anti-HCV nucleosi source ↗
Jul 10, 2019 NIH award 5R44AI129024-03 FY2019: $995,099 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent Zika virus specific nucl source ↗
Jul 19, 2018 NIH award 5R44AI129024-02 FY2018: $995,099 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent Zika virus specific nucl source ↗
Aug 18, 2017 NIH award 1R44AI129024-01A1 FY2017: $993,605 awarded for that fiscal year; activity R44 (SBIR); PI KLUMPP, KLAUS; recipient as written: RIBOSCIENCE, LLC, PALO ALTO, CA. Advancing a novel potent Zika virus specific nu source ↗